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R
obert Turner (1938–1999) was a remarkable
man. Although he is perhaps best known for the
groundbreaking UK Prospective Diabetes Study
(UKPDS), the breadth and depth of his contribu-
tions to diabetes research are remarkable. It is a privilege
for us, just a few of his many close friends and colleagues,
to be able to review his contributions as a scientist and to
remember him as a unique human being. His seminal
discoveries spanned three broad areas of diabetes re-
search—namely, the physiology of insulin secretion, the
etiopathogenesis of type 2 diabetes, and the clinical man-
agement of diabetes. In all of these areas, his combination
of intense curiosity, intelligence, indefatigability, and pas-
sion for improved patient care led to landmark discoveries
that have withstood the test of time.
Robert was a medical student in Cambridge and under-
took his clinical training and MD research at the Middlesex
Hospital in London with Dr. John Nabarro; his thesis was
entitled “Plasma Glucose Control of Insulin Secretion in
Man.” The interactions of insulin and glucose occupied
much of his physiological interests in those early days. His
early mathematical examination of insulin delivery rate (1)
was rediscovered many years later, and the concepts of
feedback control were brilliantly exempliﬁed with ﬁsh
insulin, which cleared glucose but did not cross-react with
insulin assays, thus allowing endogenous insulin to be
assayed (2). In these early days, through exposure to
scientists such as Roger Ekins, a pioneer of immunoassay,
Robert was discovering that lab-based techniques were the
window into complex in vivo interactions.
He moved to Oxford in the early 1970s and began to
develop the Diabetes Research Laboratory (DRL), which,
from humble beginnings, became one of the world’s lead-
ing centers for diabetes research. The DRL began to hum
with activity as the charcoal separation assay developed
when Robert was working with Ekins at the Middlesex
was further reﬁned and perfected (3). C-peptide assays
then came online, and the complex interactions between
glucose and insulin began to be delineated and modeled.
Robert attracted enthusiastic young clinical researchers
such as Rury Holman and David Matthews with a like-
minded bent toward mathematical understanding of phys-
iology, and their studies of feedback models of the “liver-
cell loop” (4) and the description of insulin oscillations
(5–7) proved to be seminal observations that continue to
inﬂuence physiological thinking to this day. These were
further formalized and delineated in the homeostasis
assessment (HOMA) and continuous infusion glucose
model assessment (CIGMA) models (8,9) that are now
used widely. The original article describing HOMA has
been cited 4,600 times (8). Importantly, these observa-
tions reﬂected Robert’s philosophical view that diabetes
should be considered as an endocrine disorder (indeed,
the most important endocrine disease) involving dysfunc-
tion of the endocrine cells producing the critical hormone
insulin. That may seem obvious now, but at that time,
there was a widespread (and entirely false) hierarchical
division in the U.K between “clever endocrinologists” who
worked on fascinating but relatively uncommon endocrine
disorders requiring deep thinking and sophisticated inves-
tigation, and seemingly worthy but intellectually pedes-
trian “sugar doctors” who struggled to look after vast
numbers of patients with a common but rather uninterest-
ing disease. Robert once commented that he would not
rest until a clinician seeing a patient with diabetes would
be fueled by the same desire to understand its mechanisms
as was an endocrinologist when seeing a new patient with
Cushing’s syndrome.
Although Robert was equally interested in improving the
clinical care of patients with type 1 or type 2 diabetes, he
realized quite early on that he was not an immunologist
and that he would be most usefully employed working out
why people developed type 2 diabetes. As was so often the
case, Robert’s views went against the mainstream but
turned out to be right. For decades, during which the
concept of insulin resistance came to utterly dominate
international thinking about the pathogenesis of type 2
diabetes, Robert and his colleagues, with a small but
insightful band of international colleagues (including Erol
Cerasi, Gordon Weir, and Dan Porte) continued to empha-
size the critical importance of inherent defects in pancre-
atic -cell function as a key etiological factor in the
disease (10). It is sad that he did not live to see the results
of the recent genome-wide association studies, which have
ﬁnally vindicated his view that the principal source of
inherited variation predisposing to type 2 diabetes is likely
to be in genes involved in islet function (11). Robert’s work
on the etiopathogenesis of type 2 diabetes can now be
seen as a coherent and prescient body of work that was
ahead of its time. With Rury Holman and David Matthews,
he characterized the nature of the quantitative and quali-
tative defects in -cell function in patients at the early
stages of type 2 diabetes (4,12). Stephen O’Rahilly joined
the team as a research fellow, and together they demon-
strated that such -cell defects were also present in
nondiabetic ﬁrst-degree relatives of patients with type 2
diabetes, suggesting that such defects were inherent to the
disease process (13). Robert was never content to restrict
himself to physiological observation and wanted to have a
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one of the ﬁrst to administer glucagon-like peptide-1 to
individuals with diabetes (14,15), with results that are the
cornerstone of much current therapeutic interest. He was
never very enthusiastic about animal models and felt that
the greatest insights would come from the study of human
material. “I‘m not very interested in rats,” he often said.
Anne Clark joined the DRL in 1981 and undertook pains-
taking and groundbreaking work on the histology of the
pancreas in human type 2 diabetes, quantitating and
emphasizing the potential importance of the long-
neglected islet amyloid that was characteristic of the
disease (16). Anne and Robert encouraged Garth Cooper,
a research fellow recently arrived from New Zealand, to
work with Ken Reid in the Medical Research Council
Immunochemistry Unit to see if the protein component of
islet amyloid could be isolated and characterized. Coo-
per’s quest was successful, and the discovery of islet
amyloid polypeptide/amylin (17) had “spin off” conse-
quences for which long-term effects (if perhaps through
circuitous routes) are now having beneﬁcial impacts on
patient care through discoveries emanating from Amylin
Pharmaceuticals.
Robert was always motivated by the desire to push the
science of human diabetes forward and was never con-
strained by parochial instincts to keep things “in house.”
Oxford was well placed to exploit the molecular biological
revolution of the 1980s, and Robert, realizing that the DRL
needed to engage with this ﬁeld, generously supported
Steve O’Rahilly to move to the hematology department at
the John Radcliffe hospital, where Jim Wainscoat, a disci-
ple of David Weatherall, the father of U.K. human molec-
ular genetics, was developing his laboratory. Using the
family samples that had been collected for physiological
studies, O’Rahilly started to undertake some of the ﬁrst
(and very naive) DNA polymorphism–based linkage stud-
ies in type 2 diabetes. These studies had the advantage of
novelty but the downside of negative results. However, a
couple of years later, Andrew Hattersley joined the DRL as
a research fellow and, again working in the Wainscoat lab,
undertook the linkage study that led to the identiﬁcation of
the glucokinase gene (simultaneously with Philippe
Froguel, working in France) as the ﬁrst deﬁned monogenic
disorder leading to human diabetes (18). Diabetes genetics
rapidly became an international collaborative effort, and
the Oxford lab made important contributions to the dis-
covery of other maturity-onset diabetes of the young
(MODY) genes led by Graham Bell in Chicago and Froguel
(19).
Robert remained an active clinician throughout his
professional life, running a diabetes clinic at the John
Radcliffe hospital and participating in the general medical
rota at the hospital. His research was always motivated by
a passionate desire to improve patient care. He was an
international authority on the diagnosis of spontaneous
hypoglycemia (2,20,21) and coauthored with George Al-
berti and Derek Hockaday a seminal paper on the use of
low-dose insulin for the treatment for diabetic ketoacido-
sis (22). Unknown to many people is the fact that, having
been intrigued by a toy cash register, he inspired the
development of the ﬁrst automatic lancet for ﬁngerprick
blood testing. However, his greatest contribution to the
care of patients with diabetes was his demonstration that
improved glycemic control of type 2 diabetes resulted in
their improved clinical outcome. In 1976, Robert, while
feeling unwell in Delhi, had scribbled some notes on a
small slip of paper. It was the outline of the UKPDS (23)
that he saw come to fruition 21 years later (24–27). The
question was conceptually simple, but its answer was to
have a profound impact on patient care. Would improved
glycemic control in patients with type 2 diabetes convinc-
ingly result in improved morbidity and mortality? The
answer was yes, and millions of patients now beneﬁt from
the implementation of the principles established by this
study. Few clinicians outside Oxford know of the super-
human efforts (often appearing Sisiphyean) that Robert
made to convince a multiplicity of anxious funders to
initiate and continue to support this study. He once
calculated, only 10 years into the study, that he had written
his own body weight in grant applications. No single
agency would fund the study. It was patched together from
the Medical Research Council and charitable and indus-
trial sources with invaluable support from the National
Institutes of Health, which was imaginative in its interna-
tional outlook. It lurched from funding crisis to funding
crisis, but throughout this purgatory, Robert, when turned
down (as he often was), would always say, “They actually
didn’t mean ‘no.’ What they meant was, if we come back
with this or that alteration, they will give us some money.”
As well as the simple and clear bottom line results of the
UKPDS, this study has generated more than 80 scientiﬁc
papers, illuminating important aspects of the natural his-
tory of diabetes and its associated complications and risk
factors (28,29).
In this brief article, we hope we have captured a ﬂavor
of the major scientiﬁc accomplishments of Robert Turner:
a manifestly extraordinary clinician-scientist and mentor.
However, impressive as this account is, we felt that we
could not put this article to bed without some more
personal testaments.
D.R.M.’s comments. On a more personal note, I ﬁrst met
him in my days as a medical student when he was one of
the younger clinical staff members undertaking teaching.
He took a close interest in the skills of clinical work; he
was keen to teach and was friendly and approachable. He
became a medical tutor at the Radcliffe Inﬁrmary and
wrote a succinct gem of a book, Lecture Notes on History
Taking and Examination (30), which many of us used as
our basic primer of clinical skills. He was a delight to work
for clinically, and he and David Weatherall instilled the
sense of camaraderie so necessary for a successful “ﬁrm.”
He took over the Regius Professor’s laboratory when
Richard Doll was the incumbent. Many assays were devel-
oped, and large throughput was the order of the day.
Insulin-free plasma for the assays was a necessity, and this
could be generated from random blood samples, spun
down, with the plasma treated with activated charcoal.
One day, Melanie Burnett, our longstanding, long-suffering
assayist, showed me a centrifuge cuvette of compacted
red cells and supernatant plasma. The red cells occupied
only a small proportion. The sample turned out to be from
Robert. A tour through the labs revealed that everyone
was using him as a ready source of plasma. His hemoglo-
bin turned out to be the wrong side of 10 g. He had to go
on iron, and we had to enforce a moratorium. No one was
to bleed the boss!
Research meetings were a great forum and a wonderful
training arena. Anyone could say anything and challenge
anything—and did. Robert used to love it. He would think
and change his mind and debate and turn ideas over. He
was passionately interested in diabetes and its causes and
its physiology.
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that he was a man of true and unstoppable determination.
It was planned as a 10-year study in total, but with
progressive recruitment and attrition, it took 20 years.
There were many naysayers, and one always heard grum-
blings that, because money had been given to the UKPDS,
other important work had not been funded—the important
work in question always and unaccountably belonging to
the complainant. Robert orchestrated the triumphant suc-
cess of the UKPDS at the European Association for the
Study of Diabetes (EASD) meeting in 1998 and tragically
died the next year while visiting the U.S. to present more
results there.
Those of us who worked with Robert for decades will
always be deeply grateful to him. He had an insatiable
enthusiasm for research, a broadness of mind, exuberance
under challenge, a humorous banter in debate, and an
unstoppable determination. He was generous, clever, self-
effacing, and kind. He is still much missed.
G.C.W.’s comments. It is most unusual for a postdoctoral
fellow to serve as the key mentor of a younger postdoc-
toral fellow, but of course Robert was most unusual. My
initial research assignment in the Diabetes Unit at Massa-
chusetts General Hospital was to work on insulin-stimu-
lated glucose transport, but my rescue from that fate was
facilitated by this charming, energetic Englishman. Rob-
ert’s fascination with islets and insulin secretion capti-
vated me. His project was to stimulate the growth of new
-cells, building on the hypothesis that “intermediate
cells” in pancreatic ducts could make new islets when rats
were fed soybean meal, which inhibited trypsin activity.
Sadly, his prescient efforts on what is now the hot topic of
neogenesis did not lead to much—except lab nooks and
crannies full of soybean meal and appreciative cock-
roaches. Within a short time, Robert’s infectious nature
took hold of me, and I was allowed by my generous lab
chief, Donald Martin, to work on islets, in particular, the
glucagon section. Paying attention to Robert’s lessons
about rigorous approaches to radioimmunoassays and
using his charcoal striping method, I stumbled into ﬁnding
that Roger Unger’s glucagon assay results with the famous
30K antibody were much too high because of an interfer-
ing factor. This impudent assertion provoked considerable
consternation but turned out to be correct.
That time was the beginning of a treasured friendship
between Robert, Jennie, Susan Bonner-Weir, and myself,
which led to wonderful times skiing in France and meeting
for vacations at our country house in Vermont and in
Scotland, Oxford, and Boston. This was enhanced by their
two sons and our daughters being of similar age. I still
can’t believe that Robert and I found double black dia-
mond ski runs for which neither of us had the skill; yet,
somehow we survived. Anyone familiar with Robert and
Jennie can appreciate the range of our conversations on
every conceivable subject. Among all of this were count-
less discussions about our mutual favorite subject, diabe-
tes. For us, the primacy of the -cell in the pathogenesis of
type 2 diabetes was obvious from the beginning, but we
frequently talked long into the night about virtually every-
thing having to do with diabetes. A dominant theme was
the patient with diabetes. Not only did he speak affection-
ately about individual patients under his care, but his
research was always directed toward something that
would improve their lives. I have been privileged, along
with Rury, David, and a few others, to follow in detail the
entire progression of the UKPDS. Robert’s single-minded
tenacity and passion in the face of seemingly insurmount-
able obstacles astonished me. It was so fortunate that he
lived to see his success. One of our most special times
together was in the spring before he died; he and Jennie
followed his time as Joslin’s Marble Visiting Professor,
with a visit to see us in Vermont for a weekend. Susan and
I miss him terribly.
S.O.R’s comments. In 1983, I took an afternoon off from
my clinical duties as a senior house ofﬁcer (resident) at the
Hammersmith Hospital in London to see Robert, having
been advised by a fellow senior house ofﬁcer who had
been his intern that he was a “really nice and interesting
bloke!” I was an Irish medical graduate, with few connec-
tions in the U.K., absolutely no research experience, and a
vague notion that “doing some research” might be impor-
tant if I wanted to be a good hospital physician. Given my
status as a scientiﬁc tyro, there was absolutely no chance
that I could obtain any competitive funding to do research,
but Robert spotted something in me and committed to
funding me for a year out of his “back pocket” with a vague
aspiration that we would see where things might go. The
following 5 years in Oxford changed my life. The excite-
ment of lab meetings where Robert, David Matthews, Rury
Holman, Anne Clark, and lots of bright fellows would
“ping-pong” ideas for hours on end was thrilling. After 6
months of this, I reﬂected on the fact that someone was
paying these people a living wage for having fun. I decided
I wanted a piece of this action, and my career aspirations
changed dramatically and irrevocably. Robert’s intellec-
tual and personal generosity was hugely inspiring. On
many a Saturday morning, when I had convinced an entire
family to come to Oxford for CIGMA tests, Robert, know-
ing the skeleton staff we had, would just “appear” to help
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and Jennie made their home a welcoming haven for me
and many other waifs and strays from all over the planet.
Robert had another long-lasting effect on my life. Suzy
Oakes, who administered the UKPDS from its early days
with a passionate commitment inspired by Robert, was
inexplicably diverted from this vocation in 1990 to join me
in Boston, where we married.
Conclusions. We now live in an era in which “transla-
tional research” has ﬁnally taken center stage in the world
of biomedical science. There is widespread concern about
the global dearth of academic clinicians who can under-
stand and illuminate the fundamental biology of disease
and also translate that understanding into clinical beneﬁt.
Such rare individuals are now nurtured and treasured like
ineffectually breeding pandas. It is tragic that Robert’s
premature death occurred at precisely the time when this
realization had dawned on the world leaders of biomedical
science who had perhaps been temporarily blinded by the
beauty of “pure” science to the importance of focusing on
human suffering and its alleviation. It is inexpressibly sad
that Robert did not live to see the full and formal appre-
ciation of his remarkable contributions to diabetes re-
search and to his mentorship of the next generation of
leaders in this ﬁeld. Internal and external accolades such
as his professorship at Oxford and distinctions bestowed
by international organizations came at an inexplicably late
stage in his career. Had he still been with us, he would
have been increasingly seen as a unique exemplar of
clinical science and been garlanded with many more
glittering prizes. Knowing Robert as we did, however, it
would have been of much more importance to him to have
“made a real difference.” This he certainly did—to the lives
of innumerable patients with diabetes living today and to
the improved care of future patients through the work of
clinicians and scientists on whom he has had a profound
and irrevocable inﬂuence.
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